Comorbidities in rheumatoid arthritis: the RBSMR studyHaddani Fz, Niamane R Hassikou H, Maghraoui Ei et al.|International Journal of Clinical Rheumatology|2020Cited by 11
Manifestations cardiaques du syndrome hyperéosinophilique essentielTaoufik Harzy, N. Hajjaj‐Hassouni, F. Allali et al.|La Revue de Médecine Interne|2004Cited by 11
Discontinuation of biologic therapy in patients with rheumatoid arthritis and ankylosing spondylitis: analysis from multicenter cohort studyN. El Ouardi, A. Bezza, R. Niamane et al.|Rheumatology International|2022Cited by 11
One-year direct costs of biological therapy in rheumatoid arthritis and its predictive factors: data from the Moroccan RBSMR registryS. Fellous, F. Allali, Hanan Rkain et al.|Rheumatology International|2021Cited by 10
Prevalence of latent tuberculosis before biotherapy initiation in rheumatoid arthritis and spondyloarthritis: data from the Moroccan biotherapy registryLamia Oulkadi, R. Bahiri, I. Ghozlani et al.|Rheumatology International|2021Cited by 9